June 30, 2020

Ophthalmic Consultants, P.A. and its principal Robert K. Snyder have agreed to pay $4.8 million to resolve claims that they unlawfully billed federal healthcare programs for the drugs ranibizumab (Lucentis®) and aflipercept (Eylea®).  While the drugs are sold in single-use vials, defendants used single vials to provide doses to multiple patients, allowing them to obtain excessive reimbursement from Medicare, TRICARE, and the Federal Employees Health Benefits Program.  USAO MD FL

Tagged in: Dosage Fraud, FCA Federal, Healthcare Fraud, Medical Billing Fraud, Pharma Fraud, Provider Fraud,